研究者総覧 - 大津　智

オオツ　サトシ
大津　智

所属大分大学医学部附属病院中診特診・腫瘍センター

職種講師

論文
論文	Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301). Scientific reports 15 (1),3427-3427頁 2025/01/27
論文	Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302). Therapeutic advances in medical oncology 17,17588359251320768-17588359251320768頁 2025
論文	Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. Scientific reports 14 (1),5311-5311頁 2024/03/04
論文	A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G. Targeted oncology 19 (2),181-190頁 2024/03
論文	Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Scientific reports 13 (1),19399-19399頁 2023/11/08
論文	Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer. Cancers 15 (18) 2023/09/14
論文	Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. International journal of clinical oncology 28 (8),1073-1081頁 2023/08
論文	Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future oncology (London, England) 19 (23),1593-1600頁 2023/07
論文	Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321. Cancer medicine 12 (14),14988-14999頁 2023/07
論文	C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. Scientific reports 13 (1),8815-8815頁 2023/05/31
論文	Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Anticancer research 43 (4),1817-1826頁 2023/04
論文	Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Oncology 101 (1),22-31頁 2023
論文	A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site. Japanese journal of clinical oncology 52 (12),1416-1422頁 2022/12/05
論文	Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. International journal of clinical oncology 27 (9),1450-1458頁 2022/09
論文	Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC cancer 22 (1),19-19頁 2022/01/03
論文	Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study). Journal of geriatric oncology 13 (1),82-87頁 2022/01
論文	Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Pancreas 50 (7),957-964頁 2021/08/01
論文	Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Anticancer research 41 (7),3573-3582頁 2021/07
論文	Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. International journal of clinical oncology 26 (5),951-953頁 2021/05
論文	Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer science 110 (11),3565-3572頁 2019/11
論文	Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 22 (4),817-827頁 2019/07
論文	Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. Cancer science 110 (3),1032-1043頁 2019/03
論文	A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology 77 (6),1157-64頁 2016/06
論文	Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab. Japanese clinical medicine 5,19-23頁 2014
論文	CD34-negative solitary fibrous tumour resistant to imatinib. BMJ case reports 2013 2013/07/05
論文	Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report. BMC gastroenterology 10,128-128頁 2010/11/01
論文	Extramedullary plasmacytoma as an uncommon cause of gastrorrhagia. Internal medicine (Tokyo, Japan) 49 (15),1679-80頁 2010
論文	Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. Helicobacter 11 (5),436-40頁 2006/10
論文	Transfer of antigen-pulsed dendritic cells induces specific T-Cell proliferation and a therapeutic effect against long-term Helicobacter pylori infection in mice. Infection and immunity 74 (2),984-93頁 2006/02